Alejandro serves as ReFED’s Capital, Innovation, & Engagement Manager, working to spur investment in the food waste sector. In his position, he works to contribute to the Insights Engine and build relationships with solution providers. He brings six years of technology investment banking, equity research and sales, and trading experience, including time at TD Securities, CI Investments, and RBC Capital Markets.

Chris Malins has worked in the alternative fuels space for 12 years and holds a PhD in Applied Mathematics from the University of Sheffield. He is a former Fuels Lead for the International Council on Clean Transportation and has been directly involved in the development of the California Low Carbon Fuel Standard, ICAO’s CORSIA, the UK Renewable Transport Fuel Obligation and the EU’s Renewable Energy Directive and Fuel Quality Directive. His consultancy Cerulogy works on climate and alternative fuel policy for clients in business, government and the NGO sector, specialising in alternative fuel sustainability and in advanced alternative fuel commercialization policy.

Doug Arent is the deputy associate laboratory director for the Scientific Computing and Energy Analysis Directorate at the National Renewable Energy Laboratory (NREL), as well as a senior associate (non-resident) with the CSIS Energy Security and Climate Change Program. Previously, he was director of the Joint Institute for Strategic Energy Analysis at NREL.

He specializes in strategic planning and financial analysis, clean energy technologies, energy and water issues, and international and governmental policies. From 2006 to 2010, he was director of the Strategic Energy Analysis Center at NREL. In addition to his NREL responsibilities, he is an author and expert reviewer for the Intergovernmental Panel on Climate Change (IPCC) Special Report on Renewable Energy and a member of the U.S. government review panel for the IPCC reports on climate change.

Prior to joining NREL, he was a management consultant to clean energy companies, providing strategy, development, and market counsel. Previous positions include: director of strategic marketing and business development at Network Photonics; director of media gateway products and strategic planning manager at Lucent Technologies (now Avaya); and vice president of business development for Amonix Inc.

Dr. Ronald A. DePinho is a distinguished university professor and past president at MD Anderson Cancer Center. Ron is a global health leader, entrepreneur, physician and leading scientist in the fields of cancer and aging. In addition to his research, he has launched 3 biotech companies (Tvardi, Asylia, and Nirogy) focused on cancer, inflammation and fibrosis, with potential applications to COVID-19.

He specializes in strategic planning and financial analysis, clean energy technologies, energy and water issues, and international and governmental policies. From 2006 to 2010, he was director of the Strategic Energy Analysis Center at NREL. In addition to his NREL responsibilities, he is an author and expert reviewer for the Intergovernmental Panel on Climate Change (IPCC) Special Report on Renewable Energy and a member of the U.S. government review panel for the IPCC reports on climate change.

Prior to joining NREL, he was a management consultant to clean energy companies, providing strategy, development, and market counsel. Previous positions include: director of strategic marketing and business development at Network Photonics; director of media gateway products and strategic planning manager at Lucent Technologies (now Avaya); and vice president of business development for Amonix Inc.

Dr. Gilligan is founder and CEO at Material Evolution, a sustainable concrete company. Her work encompasses the use of waste materials and new ways of creating building materials. She has published and exhibited her work globally while working with some of the world's most globally impactful companies. She has deep domain expertise and is using that to change how materials are developed.

Warner C. Greene, M.D., Ph.D., is the Nick and Sue Hellmann Distinguished Professor of Translational Medicine and Director of the Michael Hulton-Gladstone Center for HIV Cure Research.

Greene served as the founding director of the Gladstone Institute of Virology and Immunology from 1992-2018. Other appointments include Professor of Medicine, and Microbiology and Immunology at the University of California, San Francisco.

Although most of his career was devoted to HIV research, Dr. Greene’s laboratory has rapidly pivoted much of his work to the challenge posed by the SARS-CoV-2 pandemic and the COVID-19 disease it produces.